Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients (MEL58)

This study has been completed.
University of Virginia
National Cancer Institute (NCI)
Oncovir, Inc.
Information provided by (Responsible Party):
Craig L Slingluff, Jr, University of Virginia Identifier:
First received: April 24, 2012
Last updated: August 11, 2016
Last verified: August 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2014
  Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)